Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
28
Oct |
Advance Toward A Breath Test To Diagnose Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Scientists are reporting the development and successful tests in humans of a sensor array that can diagnose multiple sclerosis (MS) from exhaled breath, an advance that they describe as a landmark in the long search for a fast, inexpensive and non-invasive test for MS — the most common neurological disease in young adults. Their report appears in the journal ACS Chemical Neuroscience…
|
18
Mar |
Funding For Cutting-Edge Diagnostic Tools To Improve Astronaut Health, And For The Early Detection And Treatment Of Disease On EarthCategory: Multiple Sclerosis | Leave a Comment |
Seven new research projects on regenerative medicine and nanomedicine received $16 million in funding. The studies, co-funded by the Canadian Institutes of Health Research (CIHR) and the Canadian Space Agency (CSA), were announced at the University of Toronto by Dr. Colin Carrie, Member of Parliament for Oshawa; Dr…
|
8
Jun |
Simple Eye Test Measures Damage From Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study…
|
7
Apr |
Multiple Sclerosis: Chronix Biomedical’s Serum DNA Assays Monitor Disease Activity And Treatment ResponseCategory: Multiple Sclerosis | Leave a Comment |
Chronix Biomedical has announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS)…
|
4
Nov |
Virtual Reality Helps MS Patients Regain Stability While Walking, Medigait LLC ClaimsCategory: Multiple Sclerosis | Leave a Comment |
Studies performed over the last few years show many Multiple Sclerosis (MS) patients no longer have to live with a meandering or unsteady gait caused by their disease. According to a study published in the highly acclaimed medical journal “Neurology”, closed-loop visual feedback helps MS patients improve their walking. Both stride length and walking speed improved dramatically helping MS patients walk safely.
|
29
Sep |
Betaseron(R) To Offer The Thinnest Needle In Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.
|
29
Sep |
Betaseron(R) To Offer The Thinnest Needle In Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.
|
29
Sep |
Betaseron(R) To Offer The Thinnest Needle In Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.
|
29
Sep |
Betaseron(R) To Offer The Thinnest Needle In Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.
|
29
Sep |
Betaseron(R) To Offer The Thinnest Needle In Multiple SclerosisCategory: Multiple Sclerosis | Leave a Comment |
Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron(R)* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.